Phosphoprotein phosphatase 2A: A novel druggable target for Alzheimer's disease

Future Medicinal Chemistry

Volumn 3, Issue 7, 2011, Pages 821-833

  Voronkov, Michael ^a   Braithwaite, Steven P ^a   Stock, Jeffry B ^a,b  

^a Signum Biosciences   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TETRALONE DERIVATIVE; 4 NITROPHENYL PHOSPHATE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CERAMIDE; GLYCOGEN PHOSPHORYLASE; HEPARIN; MEMANTINE; MESSENGER RNA; METAL ION; PECTINESTERASE; PHOSPHOPEPTIDE; PHOSPHOPROTEIN PHOSPHATASE 2A; PHYTOSPHINGOSINE; POLYAMINE; QUINOLONE; SELENATE; SPHINGOSINE; STAT3 PROTEIN; TOCOPHEROL; XYLULOSE;

ALLOSTERISM; ALZHEIMER DISEASE; AMYLOID PLAQUE; CELL CYCLE PROGRESSION; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN METHYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW;

ALZHEIMER DISEASE; CERAMIDES; ENZYME INHIBITORS; HUMANS; PROTEIN PHOSPHATASE 2; SPHINGOSINE;

EID: 79958744416     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.47     Document Type: Review

References (102)

1. Kidd PM. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern. Med. Rev. 13(2), 85-115 (2008).
2. Stewart AJ, Fox A, Morimoto BH, Gozes I. Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opin. Investig. Drugs 16(8), 1183-1196 (2007). (Pubitemid 47317011)
3. Seabrook GR, Ray WJ, Shearman M, Hutton M. Beyond amyloid: the next generation of Alzheimer's disease therapeutics. Mol. Interv. 7(5), 261-270 (2007). (Pubitemid 47607486)
4. Small SA, Duff K. Linking Ab and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60(4), 534-542 (2008).
5. Dickey CA, Petrucelli L. Current strategies for the treatment of Alzheimer's disease and other tauopathies. Expert Opin. Ther. Targets 10(5), 665-676 (2006). (Pubitemid 44479975)
6. Roder HM, Hutton ML. Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease. Expert Opin. Ther. Targets 11(4), 435-442 (2007). (Pubitemid 46487592)
7. Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 5(3), 443-457 (2008). (Pubitemid 351952490)
8. Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 323(Pt 3), 577-591 (1997). (Pubitemid 27202326)
9. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl Acad. Sci. USA 91(12), 5562-5566 (1994). (Pubitemid 24174368)
10. Li B, Chohan MO, Grundke-Iqbal I, Iqbal K. Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathol. 113(5), 501-511 (2007). (Pubitemid 46672596)
11. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83(13), 4913-4917 (1986).
12. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl Acad. Sci. USA 98(12), 6923-6928 (2001). (Pubitemid 32538318)
13. Alonso AD, Di Clerico J, Li B et al. Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J. Biol. Chem. 285(40), 30851-30860 (2010).
14. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 6(6), 464-479 (2007).
15. Bulic B, Pickhardt M, Khlistunova I et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem. Int. Ed. Engl. 46(48), 9215-9219 (2007).
16. Chang E, Congdon EE, Honson NS, Duff KE, Kuret J. Structure-activity relationship of cyanine tau aggregation inhibitors. J. Med. Chem. 52(11), 3539-3547 (2009).
17. Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E. Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem. Int. Ed. Engl. 48(10), 1740-1752 (2009).
18. Ballatore C, Brunden KR, Piscitelli F et al. Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation. J. Med. Chem. 53(9), 3739-3747 (2010).
19. Trojanowski JQ, Lee VM. Pathological tau: a loss of normal function or a gain in toxicity? Nat. Neurosci. 8(9), 1136-1137 (2005). (Pubitemid 43348128)
20. Trojanowski JQ, Smith AB, Huryn D, Lee VM. Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments. Expert Opin. Pharmacother. 6(5), 683-686 (2005). (Pubitemid 40711765)
21. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25(1), 59-68 (2007). (Pubitemid 46098893)
22. Iqbal K, Grundke-Iqbal I. Pharmacological approaches of neurofibrillary degeneration. Curr. Alzheimer Res. 2(3), 335-341 (2005). (Pubitemid 40980192)
23. Drewes G. MARKing tau for tangles and toxicity. Trends Biochem. Sci. 29(10), 548-555 (2004). (Pubitemid 39265172)
24. Haddad JJ. Mitogen-activated protein kinases and the evolution of Alzheimer's: a revolutionary neurogenetic axis for therapeutic intervention? Prog. Neurobiol. 73(5), 359-377 (2004). (Pubitemid 39106844)
25. Ferrer I, Gomez-Isla T, Puig B et al. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 2(1), 3-18 (2005). (Pubitemid 41389255)
26. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22(8), 1942-1950 (2005). (Pubitemid 41579384)
27. Tian Q, Wang J. Role of serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals 11(5), 262-269 (2002). (Pubitemid 37494393)
28. Mccluskey A, Sim AT, Sakoff JA. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J. Med. Chem. 45(6), 1151-1175 (2002). (Pubitemid 34263552)
29. Combs AP. Structure-based drug design of new leads for phosphatase research. IDrugs 10(2), 112-115 (2007). (Pubitemid 46438441)
30. Lavecchia A, Coluccia A, Di Giovanni C, Novellino E. Cdc25B phosphatase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med. Chem. 8(8), 843-856 (2008).
31. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp. Neurol. 168(2), 402-412 (2001). (Pubitemid 32289776)
32. Sontag E, Luangpirom A, Hladik C et al. Altered expression levels of the protein phosphatase 2A ABaC enzyme are associated with Alzheimer disease pathology. J. Neuropathol. Exp. Neurol. 63(4), 287-301 (2004). (Pubitemid 38429026)
33. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J. Neurochem. 65(2), 732-738 (1995).
34. Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem. 61(3), 921-927 (1993). (Pubitemid 23241228)
35. Tanimukai H, Grundke-Iqbal I, Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am. J. Pathol. 166(6), 1761-1771 (2005). (Pubitemid 40734399)
36. Wang X, Blanchard J, Kohlbrenner E et al. The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J. 24(11), 4420-4432 (2010).
37. Sontag E, Hladik C, Montgomery L et al. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J. Neuropathol. Exp. Neurol. 63(10), 1080-1091 (2004). (Pubitemid 39372592)
38. Zhou XW, Gustafsson JA, Tanila H et al. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol. Dis. 31(3), 386-394 (2008).
39. Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. Paired helical filament-like phosphorylation of tau, deposition of b/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience 69(3), 691-698 (1995).
40. Sun L, Liu SY, Zhou XW et al. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 118(4), 1175-1182 (2003). (Pubitemid 36561203)
41. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem. Sci. 24(5), 186-191 (1999). (Pubitemid 29348452)
42. Lee MS, Kao SC, Lemere CA et al. APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. 163(1), 83-95 (2003). (Pubitemid 37271436)
43. Colombo A, Bastone A, Ploia C et al. JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiol. Dis. 33(3), 518-525 (2009).
44. Braithwaite SP, Schmid RS, He DN et al. Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease. Neurobiol. Dis. 39(3), 311-317 (2010).
45. Ruvolo PP, Deng X, Ito T, Carr BK, May WS. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J. Biol. Chem. 274(29), 20296-20300 (1999).
46. Trinkle-Mulcahy L, Lamond AI. Mitotic phosphatases: no longer silent partners. Curr. Opin. Cell Biol. 18(6), 623-631 (2006). (Pubitemid 44692470)
47. Park KH, Hallows JL, Chakrabarty P, Davies P, Vincent I. Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice. J. Neurosci. 27(11), 2969-2978 (2007). (Pubitemid 46438995)
48. Chen Y, Xu Y, Bao Q et al. Structural and biochemical insights into the regulation of protein phosphatase 2A by small t antigen of SV40. Nat. Struct. Mol. Biol. 14(6), 527-534 (2007). (Pubitemid 46871815)
49. Pallas DC, Shahrik LK, Martin BL et al. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell 60(1), 167-176 (1990).
50. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353(Pt 3), 417-439 (2001). (Pubitemid 32158309)
51. Lechward K, Awotunde OS, Swiatek W, Muszynska G. Protein phosphatase 2A: variety of forms and diversity of functions. Acta Biochim. Pol. 48(4), 921-933 (2001). (Pubitemid 33602348)
52. Tsujio I, Zaidi T, Xu J, Kotula L, Grundke-Iqbal I, Iqbal K. Inhibitors of protein phosphatase-2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau. FEBS Lett. 579(2), 363-372 (2005). (Pubitemid 40092413)
53. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 257(5074), 1261-1264 (1992).
54. Lee J, Stock J. Protein phosphatase 2A catalytic subunit is methyl-esterified at its carboxyl terminus by a novel methyltransferase. J. Biol. Chem. 268(26), 19192-19195 (1993). (Pubitemid 23270686)
55. Lee J, Chen Y, Tolstykh T, Stock J. A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc. Natl Acad. Sci. USA 93(12), 6043-6047 (1996). (Pubitemid 26190799)
56. Xing Y, Li Z, Chen Y, Stock JB, Jeffrey PD, Shi Y. Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell 133(1), 154-163 (2008). (Pubitemid 351442993)
57. Tolstykh T, Lee J, Vafai S, Stock JB. Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits. EMBO J. 19(21), 5682-5691 (2000).
58. Wu J, Tolstykh T, Lee J, Boyd K, Stock JB, Broach JR. Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. Embo J. 19(21), 5672-5681 (2000).
59. Cutler RG, Kelly J, Storie K et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl Acad. Sci. USA 101(7), 2070-2075 (2004). (Pubitemid 38229016)
60. Pelech S, Cohen P. The protein phosphatases involved in cellular regulation. 1. Modulation of protein phosphatases-1 and 2A by histone H1, protamine, polylysine and heparin. Eur. J. Biochem. 148(2), 245-251 (1985).
61. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2A. J. Biol. Chem. 268(21), 15523-15530 (1993). (Pubitemid 23222045)
62. Ruvolo PP, Clark W, Mumby M, Gao F, May WS. A functional role for the B56 a-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J. Biol. Chem. 277(25), 22847-22852 (2002). (Pubitemid 34967266)
63. Chen CL, Lin CF, Chiang CW, Jan MS, Lin YS. Lithium inhibits ceramide- and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis. Mol. Pharmacol. 70(2), 510-517 (2006).
64. Mukhopadhyay A, Saddoughi SA, Song P et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 23(3), 751-763 (2009).
65. Chalfant CE, Szulc Z, Roddy P, Bielawska A, Hannun YA. The structural requirements for ceramide activation of serine-threonine protein phosphatases. J. Lipid Res. 45(3), 496-506 (2004). (Pubitemid 38337996)
66. Chalfant CE, Kishikawa K, Mumby MC, Kamibayashi C, Bielawska A, Hannun YA. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J. Biol. Chem. 274(29), 20313-20317 (1999).
67. Kamibayashi C, Estes R, Slaughter C, Mumby MC. Subunit interactions control protein phosphatase 2A. Effects of limited proteolysis, N-ethylmaleimide, and heparin on the interaction of the B subunit. J. Biol. Chem. 266(20), 13251-13260 (1991). (Pubitemid 21907336)
68. Cheng Q, Erickson AK, Wang ZX, Killilea SD. Stimulation of phosphorylase phosphatase activity of protein phosphatase 2A1 by protamine is ionic strength dependent and involves interaction of protamine with both substrate and enzyme. Biochemistry 35(48), 15593-15600 (1996). (Pubitemid 26408897)
69. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 138(7), 1303-1312 (2003). (Pubitemid 36543128)
70. Liu Q, Zhao X, Frissora F et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111(1), 275-284 (2008).
71. Habrukowich C, Han DK, Le A et al. Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. J. Biol. Chem. 285(35), 26825-26831 (2010).
72. Yoon CH, Kim MJ, Park MT et al. Activation of p38 mitogen-activated protein kinase is required for death receptor-independent caspase-8 activation and cell death in response to sphingosine. Mol. Cancer Res. 7(3), 361-370 (2009).
73. Leoni LM, Shih HC, Deng L et al. Modulation of ceramide-activated protein phosphatase 2A activity by low molecular weight aromatic compounds. Biochem. Pharmacol. 55(7), 1105-1111 (1998). (Pubitemid 28167732)
74. Bauer PI, Kirsten E, Kun E. Mechanisms of antitumor action of methyl-3,5-diiodo-4- (4'-methoxyphenoxy)benzoate: drug-induced protein dephosphorylations and inhibition of the permissive action of ceramide on growth factor induced cell proliferation. Oncol. Rep. 13(3), 465-468 (2005).
75. Guichard C, Pedruzzi E, Fay M et al. Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells. Carcinogenesis 27(9), 1812-1827 (2006). (Pubitemid 44288663)
76. Ricciarelli R, Tasinato A, Clement S, Ozer NK, Boscoboinik D, Azzi A. a-tocopherol specifically inactivates cellular protein kinase C a by changing its phosphorylation state. Biochem. J. 334(Pt 1), 243-249 (1998).
77. Kang-Woo Lee WC, Junn E, Grosso H et al. Enhanced phosphatase activity attenuates ?-synucleinopathy in a mouse model. J. Neurosci. 31(19), 6963-6971 (2011).
78. Li Z, Semmelhack V, Braithwaite SP, Stock JB. Competition between ?-tocopherol and ceramide determines protein phosphatase 2A catalytic activity. Presented at: Society for Neuroscience Annual Meeting. San Diego, CA, USA, 13-17 November 2010.
79. Usoro OB, Mousa SA. Vitamin E forms in Alzheimer's disease: a review of controversial and clinical experiences. Crit. Rev. Food Sci. Nutr. 50(5), 414-419 (2010).
80. Chohan MO, Khatoon S, Iqbal IG, Iqbal K. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Lett. 580(16), 3973-3979 (2006). (Pubitemid 43946883)
81. Nishimura M, Uyeda K. Purification and characterization of a novel xylulose 5-phosphate-activated protein phosphatase catalyzing dephosphorylation of fructose-6-phosphate,2-kinase:fructose-2,6- bisphosphatase. J. Biol. Chem. 270(44), 26341-26346 (1995).
82. Van Eersel J, Ke YD, Liu X et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc. Natl Acad. Sci. USA 107(31), 13888- 13893 (2010).
83. Corcoran NM, Hovens CM, Michael M, Rosenthal MA, Costello AJ. Open-label, Phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br. J. Cancer 103(4), 462-468 (2010).
84. Benton D. Selenium intake, mood and other aspects of psychological functioning. Nutr. Neurosci. 5(6), 363-374 (2002). (Pubitemid 35469536)
85. Akbaraly TN, Hininger-Favier I, Carriere I et al. Plasma selenium over time and cognitive decline in the elderly. Epidemiology 18(1), 52-58 (2007). (Pubitemid 46005909)
86. Cardoso BR, Ong TP, Jacob-Filho W, Jaluul O, Freitas MI, Cozzolino SM. Nutritional status of selenium in Alzheimer's disease patients. Br. J. Nutr. 103(6), 803-806 (2009).
87. Wu Y, Song P, Xu J, Zhang M, Zou MH. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J. Biol. Chem. 282(13), 9777-9788 (2007). (Pubitemid 47104626)
88. Yang X, Yang Y, Fu Z et al. Melatonin ameliorates alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J. Psychopharmacol. DOI: 10.1177/0269881110367723 (2010) (Epub ahead of print).
89. Cho DH, Choi YJ, Jo SA et al. Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition. Am. J. Physiol. Cell Physiol. 291(2), C317-C326 (2006).
90. Liu B, Arbogast LA. Progesterone decreases tyrosine hydroxylase phosphorylation state and increases protein phosphatase 2A activity in the stalk-median eminence on proestrous afternoon. J. Endocrinol. 204(2), 209-219 (2010).
91. Switzer CH, Ridnour LA, Cheng RY et al. Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene 28(43), 3837-3846 (2009).
92. Aceto N, Bertino P, Barbone D et al. Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur. Respir. J. 34(6), 1399-1407 (2009).
93. Neviani P, Santhanam R, Trotta R et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8(5), 355-368 (2005). (Pubitemid 41579831)
94. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev. 27(2), 159-168 (2008).
95. Nakashima I, Liu W, Akhand AA et al. 4-hydroxynonenal triggers multistep signal transduction cascades for suppression of cellular functions. Mol. Aspects Med. 24(4-5), 231-238 (2003). (Pubitemid 36945023)
96. Liu W, Akhand AA, Takeda K et al. Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal. Cell Death Differ. 10(7), 772-781 (2003). (Pubitemid 36850238)
97. Kowluru A, Seavey SE, Rabaglia ME, Nesher R, Metz SA. Carboxylmethylation of the catalytic subunit of protein phosphatase 2A in insulin-secreting cells: evidence for functional consequences on enzyme activity and insulin secretion. Endocrinology 137(6), 2315-2323 (1996). (Pubitemid 26155764)
98. Kitano K, Nam KY, Kimura S, Fujiki H, Imanishi Y. Sealing effects of (-)-epigallocatechin gallate on protein kinase C and protein phosphatase 2A. Biophys. Chem. 65(2-3), 157-164 (1997). (Pubitemid 27199419)
99. De Los Rios C, Egea J, Marco-Contelles J et al. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J. Med. Chem. 53(14), 5129-5143 (2010).
100. Altiok S, Xu M, Spiegelman BM. PPARg induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11(15), 1987-1998 (1997). (Pubitemid 27332985)
101. Norinder U, Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Deliv. Rev. 54(3), 291-313 (2002). (Pubitemid 34260955)
102. Vitek MPC, Dale J, Oddo J: US0144627 (2010).